Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium
Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium |
| [14-September-2025] |
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- At the 18th International lgA Nephropathy Symposium (IIgANN 2025), 7 new abstracts based on real-world evidence of NEFECON® will be presented. The 18th IIgANN will take place in Prague, Czech Republic, from September 17 to 20, 2025. The newly released results, based on clinical practices at several leading hospitals in China, offer a comprehensive overview of the efficacy and safety of NEFECON® in the treatment of IgA nephropathy (IgAN). The clinical value of NEFECON® was highlighted across three key dimensions, consistent with the new disease management strategy of "Treat the cause, Treat early, Treat long-term." In real-world clinical practice, there is strong validation of NEFECON®'s value as an etiological treatment, where early intervention is critical in reducing proteinuria and protecting renal function, and extended treatment beyond 9 months provided robust evidence supporting sustained efficacy and safety. These real-world evidence not only address the limitations of randomized controlled trials (RCTs) in clinical practice but also reinforce the new disease management strategy of "Treat the cause, Treat early, Treat long-term". They further strengthen NEFECON®'s position as the world's first etiological treatment for IgAN, providing strong scientific evidence to advance both clinical practice and global research. NEFECON® has been recommended by several authoritative treatment guidelines, including the "KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)", and the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)". NEFECON® was included in China's National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON® has been officially approved by NMPA in August 2025. NEFECON® is currently the world's first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom, as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea. Abstracts 1. Abstract Number: P-45 2. Abstract Number: P-44 3. Abstract Number: P-43 * Budesonide enteric capsules are Nefecon. 4. Abstract Number: P-63 5. Abstract Number: P-64 6. Abstract Number: P-48 7. Abstract Number: P-62 * Budesonide enteric capsules are Nefecon. About NEFECON® NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models. In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong SAR, Macao SAR, Taiwan, China and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company's core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
SOURCE Everest Medicines | ||
Company Codes: HongKong:1952,HongKong:1952.HK |
View original content:
